Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Adenocarcinoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

Thyroid Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Carcinoma, Renal Cell

Locally Advanced Melanoma

Advanced Renal Cell Carcinoma (aRCC)

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Melanoma, Skin Neoplasms

Stomach Neoplasms

Head and Neck Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Transitional Cell

Esophageal Neoplasms

Carcinoma, Non-Small-Cell Lung

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Efficacy, Team

Melanoma, Motor Activity

Head and Neck Neoplasms

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

Gastrointestinal Neoplasms

Gastrointestinal Neoplasms

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Carcinoma, Hepatocellular, Liver Diseases

Locally Advanced Gastric Cancer

Stomach Neoplasms

Brain Neoplasms

Carcinoma, Non-Small-Cell Lung

Recurrent Squamous Cell Lung Carcinoma

Neoplasm Metastasis

Kidney Neoplasms, Lung Neoplasms, Melanoma

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

Esophageal Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms, Melanoma

Advanced Colorectal Carcinoma

Clinical Trials

Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland

METAGIO

SARCO-CTI

NeoLATC

ALCG-01

FINN

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

International Multicentric Study ARON-1

Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

SURROGATE-ICI

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

A Benefit Population Atlas of nICT Versus nCT for LAGC

ProNiHN

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

URADJ

Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

DELINOR

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

The Immune Assessment of PD-1 Antibody Therapy in Tumor

APiTOXMM

Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer

EROS

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

Development and Analysis of a Stool Bank for Cancer Patients

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer

Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs

TREATMENT

I-STOP

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

ST-ICI

Microbiome Immunotherapy Toxicity and Response Evaluation

QUASAR

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

VOLUME-PRO

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer